The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Amerisource, Sarepta, BofA, Ebay, Lululemon, Juniper

Tue, 19th Mar 2013 13:21

March 19 (Reuters) - Some U.S. stocks to watch on Tuesday:

(For more market insights, including options activity, click on ; for The Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/faq23t)

FUTURES GAIN BEFORE DATA, FOCUS SHIFTS FROM CYPRUS

U.S. stock index futures edged up on Tuesday, after two daysof declines, as investors' focus shifted away from developmentsin Cyprus that may lead the country into default.

S&P 500 futures added 3.7 points. Dow Jonesindustrial average futures added 20 points and Nasdaq 100futures gained 9 points.

** AMERISOURCEBERGEN, Monday close $51.27, up 6 pctpremarket

** WALGREEN CO, Monday close $42.43, up 2 pctpremarket

** CARDINAL HEALTH INC, Monday close $46.13, down 5pct premarket

Drug distributor AmerisourceBergen signed a 10-yeardistribution deal with Walgreen Co and partner Alliance BootsABN.UL that it said would deliver $28 billion in incrementalrevenue in fiscal 2014 and give the pharmacy chains the right toacquire up to 23 percent of the company. Shares ofAmerisourceBergen rival, Cardinal Health, fell in premarkettrade on news of the contract.

** AFFYMAX INC, Monday close $2.92, down 58 pctpremarket

The drugmaker said on Monday that it was considering sellingitself or filing for bankruptcy among a range of alternatives,as it struggles to stay afloat following the recent recall ofits sole commercial product, anemia drug Omontys.

** HARVEST NATURAL RESOURCES INC, Monday close$5.49, down 40 pct premarket

The oil and gas producer said it had identified someaccounting errors and it might have to restate results for someperiods in the last three years.

Harvest Natural also estimated a full-year loss of about$9.6 million, or 26 cents per share, for 2012.

** MER TELEMANAGEMENT SOLUTIONS LTD, Monday close$5.02, down 35 pct premarket

The company, which provides products and services to managetelecommunications expenses, said one of its customers, SimpleMobile, intends to migrate its hosted billing services to itsown platform.

MTS had last year entered into a one-year agreement with thecompany, a part of TracFone, to provide hosted billing servicesfor minimum monthly payments of $300,000 for 2013. "It isunlikely that we will receive significant revenues from TracFonein 2014," MTS said in a release.

** GMX RESOURCES INC, Monday close $4, down 12.5pct premarket

The oil and gas producer reiterated that it may seekbankruptcy protection if it is not able to reach a consensualalternative for restructuring its balance sheet. The companyalso said it had not been able to file its annual report as ithad been focused on discussions with lenders and findingfinancing alternatives.

** NPS PHARMACEUTICALS INC, Monday close $9.04, up10 pct premarket

NPS has regained full worldwide rights to a pair of drugsfrom Japan's Takeda Pharmaceutical Co in exchange for$50 million in NPS common shares, the companies announced onTuesday.

Under the deal, NPS will have worldwide rights to developand sell teduglutide, a treatment for a rare condition calledshort bowel syndrome, sold in Europe as Revestive and in theUnited States as Gattex, and for an osteoporosis drug sold inEurope under the brand name Preotact.

** DSW INC, Monday close $67.05, down 8 pctpremarket

The footwear retailer said it was off to a slow start in2013 as it experienced weak sales trends in the first six weeksof the year, prompting it to forecast flat same-store sales forthe first half of the year. The company also postedfourth-quarter results that missed Wall Street expectations.

** LULULEMON ATHLETICA INC , Monday close$65.90, down 8 pct premarket

The Canadian company is pulling shipments of unexpectedlysheer women's yoga pants from its stores, in a move the athleticclothing maker said would hurt its bottom line.

** HOSPITALITY PROPERTIES TRUST, Monday close$27.19, down 7 pct premarket

The owner of hotels and travel centers said it was raisingmoney through an offering of 10 million shares to pay down debt.

** SKULLCANDY INC, Monday close $5.33, up 6 pctpremarket

The maker of trendy headphones named the head of Nike Inc's Nike+ Digital Sport as its chief executive, as it dealswith the loss of a major customer and looks to rein in costsrelated to international expansion.

** CRESTWOOD MIDSTREAM PARTNERS LP, Monday close$24.85, down 4.6 pct premarket

The company, which transports natural gas and relatedliquids, said it has started a public offering of 4.5 millioncommon units and will use the proceeds to repay debt.

** HOLLY ENERGY PARTNERS LP, Monday close $42.28,down 4 pct premarket

The company, which operates petroleum product and crudepipelines, said it plans to offer 1.87 million common units anduse the proceeds to repay debt.

** SAREPTA THERAPEUTICS INC, Monday close $33.03,up 4 pct premarket

Deutsche Bank analyst Robyn Karnauskas initiated coverage onthe company with a "buy" rating, saying its experimental drug totreat Duchenne muscular dystrophy, a genetic disorder thatcauses progressive muscle loss, is likely to get U.S. approvalby mid-2015.

"We see eteplirsen as having a better safety profile versusits competitor Drisapersen that will allow it to take majorityshare," Karnauskas wrote in a note to clients. Drisapersen isbeing tested by GlasxoSmithKline Plc in a late-stagetrial, while eteplirsen is in a mid-stage study.

** JUNIPER NETWORKS INC, Monday close $20.21, down3.5 pct premarket

Goldman Sachs downgraded the network equipment maker to"sell" from "neutral", saying Alcatel-Lucent and Cisco SystemsInc are expected to take market share from Juniper.

"We see continued share loss to Palo Alto Networks and others, as Juniper's products still have certain gapscompared to the competition, such as the reporting features,"analyst Simona Jankowski wrote in a note.

The company's expected transition to a software model mayhave a cannibalistic effect as Juniper begins to sell softwarelicenses on an as-needed basis as opposed to the traditionalmodel of up-front hardware sales, the note said. The brokeragealso cut its price target on the stock to $17 from $21.

** 8X8 INC, Monday close $6.90, up 3.2 pctpremarket

The Internet telephone company launched a new softphone appintegrating Internet phone calls with one-on-one video calling,web and video conferencing, and visual voicemail.

** EBAY INC, Monday close $50.11, up 1.8 pctpremarket

Cantor Fitzgerald upgraded the e-commerce company's stock to "buy" from "hold", saying it expects the number of activeusers of its online marketplace to increase as it adds brandedretailers and other features.

"We expect to see a positive impact on growth ininternational markets as many of these changes are rolled outoutside the U.S.," analyst Youssef Squali said in a note. Theimpact of the new "digital wallet" fee on the company's PayPalbusiness was also likely to be "manageable", Squali added.

** ELECTRONIC ARTS, Monday close $18.71, up 1.5 pctpremarket

The company behind the "Sims" and "Medal of Honor"franchises said on Monday Chief Executive John Riccitiello hadresigned after six years at the helm of the video gamespublisher.

** BANK OF AMERICA CORP, Monday close $12.56, up 1.4pct premarket

Bank of America's shares recovered slightly after Cyprus'sgovernment proposed on Tuesday to spare small savers from a taxon bank deposits, in a last-minute attempt to win parliamentarybacking for an international bailout and avoid a default and abanking collapse.

** CHARTER COMMUNICATIONS INC, Monday close 98.04,down 1 pct premarket

** LIBERTY MEDIA CORP, Monday close $110.66

Liberty Media Corp will buy a 27.3 percent stake in cableoperator Charter Communications Inc for about $2.62 billion.Liberty will pay $95.50 for each Charter share, a discount of2.6 percent to Charter's Monday close of $98.04.

** HUNTSMAN CORP, Monday close $19.26, up 1 pctpremarket

The chemical maker said its facilities in Port Neches,Texas, which were under maintenance, are now operating at normalrates. The company added that its first-quarter EBITDA would behurt by $10 million as a result of delays in maintenanceactivity.

** TWO HARBORS INVESTMENT CORP, Monday close $13.87,down 1 pct premarket

The REIT, which invests in residential mortgage-backedsecurities and residential mortgage loans, said it plans tooffer 50 million shares to raise funds for acquisitions.

** CHESAPEAKE ENERGY CORP, Monday close $22.17, down1 pct premarket

The second-largest U.S. natural gas company gave moredetails about its plan to raise $2.3 billion by selling seniornotes. It will use the proceeds to buy some of its debt due 2013and 2018.

** INTERSECTIONS INC, Monday close $11.05, down 14pct after market

The provider of indentity theft protection said on Mondayits full-year revenue will fall as much as 15 percent asregulatory scrutiny causes financial services companies to pullback on marketing its products.

** FUTUREFUEL CORP, Monday close $13.66, down 9 pctafter market

The chemicals and biofuels maker posted a fourth-quarterprofit that missed analysts' estimates as revenue from two ofits largest customers fell due to the expiration of a$1-per-gallon tax credit for biodiesel.

** USA MOBILITY INC, Monday close $12.74, down 5pct after market

The paging and wireless services provider on Monday delayedthe reporting of its fourth-quarter and full-year 2012 results,citing a "material weakness" related to its software revenuerecognition process.

The company did not provide a new date for reporting itsfourth-quarter and full-year results.

** CHIQUITA BRANDS INTERNATIONAL INC, Monday close$7.39, up 3 pct after market

The fruit and vegetable distributor's Chief Executive, EdLonergan, revealed in a regulatory filing that he had acquired50,800 shares of the company for about $367,000. The priceimplies an average purchase value of $7.22 per share. (Compiled by Pallavi Ail in Bangalore; Editing by SreejirajEluvangal)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.